Preclinical study reveals that intravitreal rhNGF preserves retinal ganglion cells and vision in a glaucoma mouse model, suggesting a durable neuroprotective therapeutic strategy.
Key Points
To evaluate the neuroprotective efficacy of a single intravitreal administration of recombinant human nerve growth factor (rhNGF) on retinal structure, visual function, oxidative stress, and inflammation in a murine model of spontaneous glaucoma.
Administered a single intravitreal dose of rhNGF in a genetic mouse model of spontaneous pigmentary glaucoma.
Evaluated visual acuity, retinal thickness, retinal ganglion cell survival, metabolic changes, oxidative stress markers, and neuroinflammation during early-stage and fully developed disease.
rhNGF attenuated visual acuity loss, preserved overall retinal thickness, and improved retinal ganglion cell survival across both early and advanced stages of glaucoma.
Treatment suppressed ocular oxidative stress and neuroinflammation, sustaining protective effects for several weeks following a single injection.